Cold Chain Expansion Will Support Cell And Gene Therapies

Published
30 Mar 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$12.11
25.9% undervalued intrinsic discount
15 Aug
US$8.97
Loading
1Y
-2.6%
7D
2.0%

Author's Valuation

US$12.1

25.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 Aug 25
Fair value Increased 12%

Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.

Shared on01 May 25
Fair value Decreased 1.62%

Shared on24 Apr 25
Fair value Increased 4.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 6.33%

Shared on09 Apr 25
Fair value Increased 4.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.78%

AnalystConsensusTarget has increased revenue growth from -4.0% to 2.9% and decreased future PE multiple from 25.4x to 21.8x.